Studies gut bacteria and immunotherapy response in several solid cancers
Observes gut bacteria and immune response in adults treated with checkpoint inhibitors.
Key facts
- Who runs it
- VastBiome
- Where
- Elizabethtown, United StatesSee the site
- Trial code
- Registry title
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 22 Nov 2021
- Expected to end
- 14 Sept 2028
- Type of study
- Observational
- Treatments tested
- Checkpoint Inhibitor, Immune
- Record updated
- 27 April 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage I-IV non-small cell lung cancer, melanoma, triple-negative breast cancer or kidney cancer who plan to start a checkpoint inhibitor, and who can give stool samples.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Stages I-IV primary non-small cell lung cancer, malignant melanoma, triple-negative breast cancer or renal cell carcinoma
- Earlier treatment
- Must plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA-4), alone or with other treatment, as approved by the FDA label
Main reasons for not taking part
- Mental incapacity
- Incarcerated individuals
- Pregnancy (by self-report)
- Active brain metastasis
- Checkpoint inhibitor given off-label or in a clinical trial, or active participation in an immuno-oncology trial or pharma-sponsored observational study
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Men or women ≥18 years of age
- Screened negative for COVID-19 symptoms at time of consent, as per institutional policy and as applicable for the duration of the COVID-19 pandemic
- Diagnosed with stages I-IV primary NSCLC, MM, TNBC or RCC
- Plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
- Able to provide informed consent and answer study questionnaires in either English or Spanish
- Able to provide stool specimens for research purposes
Who cannot take part
- Treatment with checkpoint inhibitor in off-label capacity or through a clinical/interventional trial
- Mental incapacity
- Incarcerated individuals
- Pregnancy (by self-report of pregnancy status)
- Experiencing active brain metastasis/metastases
- Active participation in an immuno-oncology clinical/interventional trial or pharma-sponsored observational study
Where in United States
- Baptist Health Clinical ResearchElizabethtown, United StatesContact: Diane Drobny, BSN, RN, OCN, CCRPTaking people
About the trial
What the trial wants to find out
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly among patients undergoing identical therapy but experiencing different outcomes. The proposed observational study builds upon these hypotheses by proposing a large cohort design to further assess the associations between the gut microbiota (composition and function), host immune system, and ICI treatment efficacy across multiple cancer types.
Treatments tested
- Checkpoint Inhibitor, Immune
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Plain-language title
- Studies gut bacteria and immunotherapy response in several solid cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 April 2022